文献速递高血压瓣膜病与结构性心脏病

利用既往心血管数据改善高血压的检出与治疗:NOTIFY-LVH随机临床试验

Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

NOTIFY-LVH 是一项在 Mass General Brigham 医疗系统内开展的实用型随机临床试验,针对既往超声心动图提示左心室肥厚(LVH)但无心肌病诊断且未用降压药的患者(n=648)。由人群健康协调员通知临床医生并提供随访支持,12 个月内干预组启动降压药比例显著高于对照组(16.3% vs 5.0%;校正 OR 3.76,95%CI 2.09-6.75,P<.001),新诊断高血压也更多(校正 OR 4.43,95%CI 2.36-8.33,P<.001)。

要点

  • 对既往超声提示 LVH 且未用降压药者,系统通知可显著提高降压药启动率。
  • 干预组新诊断高血压风险约为对照组的 4.4 倍。
  • 心肌病诊断率两组无显著差异。

核心结论

  • 由中心化人群健康协调员主导、针对既往超声心动图 LVH 患者的通知与临床支持路径,可提高高血压的初始治疗。

研究设计与样本

  • NOTIFY-LVH 为双臂实用型随机临床试验,2023 年 3 月至 2024 年 6 月在 Mass General Brigham 医疗系统开展,随访 12 个月。
  • 纳入既往超声心动图有 LVH、无明确心肌病诊断且未接受降压药治疗、隶属该医疗系统初级保健的患者,共 648 例随机(干预组 326 例,对照组 322 例)。
  • 干预为人群健康协调员联系干预组患者的临床医生,告知 LVH 并提供随访协助,同时提供包括 24 小时动态血压监测或心内科转诊的临床支持路径。

主要发现

  • 12 个月内,干预组 53 例(16.3%)启动降压药,对照组 16 例(5.0%),校正 OR 3.76(95%CI 2.09-6.75,P<.001)。
  • 干预组更易被诊断高血压,校正 OR 4.43(95%CI 2.36-8.33,P<.001)。
  • 心肌病诊断率两组无显著差异。
  • 患者平均(SD)年龄 59.4(10.8)岁,女性 248 例(38.3%);基线 102 例(15.7%)有高血压诊断,109 例(20.1%)平均门诊血压≥130/80 mm Hg。

临床怎么用

  • 可将既往超声心动图提示的 LVH 作为触发点,由协调员通知临床医生并配套动态血压监测或心内科转诊路径,以促进高血压识别与治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypertension is often underrecognized, leading to preventable morbidity and mortality. Tailored data systems combined with care augmented by trained nonphysicians have the potential to improve cardiovascular care. OBJECTIVE: To determine whether previously collected cardiovascular imaging data could be harnessed to improve the detection and treatment of hypertension through a system-level intervention. DESIGN, SETTING, AND PARTICIPANTS: The NOTIFY-LVH trial was a 2-arm, pragmatic randomized clinical trial conducted from March 2023 through June 2024 within the Mass General Brigham health care system, a multi-institutional network serving the greater Boston, Massachusetts, area. The study included individuals with a Mass General Brigham primary care affiliation who had left ventricular hypertrophy (LVH) on a prior echocardiogram, had no established cardiomyopathy diagnosis, and were not being treated with antihypertensive medications. Patients were followed for 12 months postintervention. INTERVENTION: Population health coordinators contacted clinicians of patients randomized to the intervention, notifying them of LVH and offering assistance with follow-up care. A clinical support pathway-including 24-hour ambulatory blood pressure monitoring or cardiology referrals-was provided to aid LVH evaluation. MAIN OUTCOMES AND MEASURES: The primary outcome was the initiation of an antihypertensive medication. Secondary outcomes included new hypertension and cardiomyopathy diagnoses. RESULTS: A total of 648 patients were randomized-326 to the intervention and 322 to the control. Mean (SD) patient age was 59.4 (10.8) years and 248 patients (38.3%) were female. A total of 102 patients (15.7%) had a baseline diagnosis of hypertension and 109 patients (20.1%) had a mean outpatient blood pressure of 130/80 mm Hg or higher. Over 12 months, 53 patients (16.3%) in the intervention arm were prescribed an antihypertensive medication vs 16 patients (5.0%) in the control arm (adjusted odds ratio [OR], 3.76; 95% CI, 2.09-6.75; P < .001). Individuals in the intervention group were also more likely to be diagnosed with hypertension (adjusted OR, 4.43; 95% CI, 2.36-8.33; P < .001). Cardiomyopathy diagnoses did not significantly differ between groups. CONCLUSIONS AND RELEVANCE: In the NOTIFY-LVH randomized clinical trial, a centralized population health coordinator-led notification and clinical support pathway for individuals with LVH on prior echocardiograms increased the initial treatment of hypertension. This work highlights the potential benefit of leveraging preexisting but potentially underutilized cardiovascular data to improve health care delivery through mechanisms augmenting the traditional ambulatory care system. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05713916.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Berman AN, Hidrue MK, Ginder C, et al. Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension: The NOTIFY-LVH Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40162953. doi:10.1001/jamacardio.2025.0871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。